{"id":15,"date":"2007-01-19T16:19:46","date_gmt":"2007-01-19T20:19:46","guid":{"rendered":"http:\/\/piel-l.org\/blog\/?p=15"},"modified":"2007-01-19T18:20:03","modified_gmt":"2007-01-19T22:20:03","slug":"efficacy-and-safety-of-long-term-treatment-with-cyclosporin-a-for-atopic-dermatitis","status":"publish","type":"post","link":"https:\/\/piel-l.org\/blog\/15","title":{"rendered":"Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis"},"content":{"rendered":"<p><strong>2H3HJournal of the European Academy of Dermatology and Venereology<br \/> Volume 21 Issue 1 Page 85 &#8211; January 2007<br \/> DJ Hijnen, O ten Berge, L Timmer-de Mik, CAFM Bruijnzeel-Koomen, MS de Bruin-Weller<\/strong><\/p>\n<blockquote><p>En este interesante trabajo realizado en Dermatology\/Allergology, University Medical Center, Utrecht, 3508 GA Utrecht, l.  Holanda, con un n\u00famero importante de pacientes (73 pacientes, 31 mujeres y 42 hombres con un promedio de edad de 33.8 a\u00f1os, con severas formas de dermatitis at\u00f3pica refractarias a los tratamientos convencionales, recibiero ciclosporina A, con una duraci\u00f3n promedia de 1,3 a\u00f1os. El tratamiento fue exitoso en 53\/73. Despu\u00e9s de retira la ciclosporina 43\/73 experimentaron reca\u00edda y 33\/73 pacientes expei,emtaron remisiones cl\u00ednicas hasta despu\u00e9s de 3 mese. No hubo correlaci\u00f3n entre la duraci\u00f3n del tratamiento y nefrotoxicidad o hipertensi\u00f3n arterial. Sorprendentemente 6\/73 experimentaron un fen\u00f3meno de rebote .<br \/> Nosotros en Venezuela usamos poco la Ciclosporina A, el grupo del Hospital Universitario de Caracas, liderizado por el Dr. Francisco Gonz\u00e1lez Otero present\u00f3 en varoas oportunidades su experiencia con excelentes resultados en esta misma patolog\u00eda y con dosis bajas (2-3 mg\/kg\/peso\/d\u00eda) <\/p><\/blockquote>\n<table cellspacing=\"0\" cellpadding=\"0\">\n<tr>\n<td><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/mail.google.com\/mail\/images\/pdf.gif\" width=\"16\" height=\"16\" \/><\/td>\n<td width=\"7\">&nbsp;<\/td>\n<td><strong>articulo_2.pdf<\/strong><br \/> 16K    <a href=\"\/blog\/wp-content\/uploads\/2007\/01\/139\/articulo_2.pdf\" target=\"_blank\">Descargar documento<\/a> <\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>2H3HJournal of the European Academy of Dermatology and Venereology Volume 21 Issue 1 Page 85 &#8211; January 2007 DJ Hijnen, O ten Berge, L Timmer-de Mik, CAFM Bruijnzeel-Koomen, MS de Bruin-Weller En este interesante trabajo realizado en Dermatology\/Allergology, University Medical Center, Utrecht, 3508 GA Utrecht, l. Holanda, con un n\u00famero importante de pacientes (73 pacientes, &hellip;<\/p>\n","protected":false},"author":16,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[],"class_list":["post-15","post","type-post","status-publish","format-standard","","category-articulos-cientificos"],"_links":{"self":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/15","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/comments?post=15"}],"version-history":[{"count":0,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/15\/revisions"}],"wp:attachment":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/media?parent=15"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/categories?post=15"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/tags?post=15"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}